Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALIQOPA vs FASTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALIQOPA (copanlisib) is a phosphatidylinositol 3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms. It induces apoptosis and inhibits proliferation in malignant B-cell lines.
Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.
Relapsed follicular lymphoma (FDA accelerated approval) in patients who have received at least two prior systemic therapies,Off-label: Other B-cell malignancies (e.g., diffuse large B-cell lymphoma, chronic lymphocytic leukemia)
Short-term adjunct in exogenous obesity,Off-label: Attention deficit hyperactivity disorder (ADHD)
60 mg intravenously over 1 hour on days 1, 8, and 15 of a 28-day cycle.
30 mg orally once daily in the morning, administered as a single dose.
Terminal elimination half-life of approximately 39 hours in patients with hematologic malignancies; supports twice-daily dosing.
Terminal elimination half-life is approximately 16-20 hours for the immediate-release formulation. With sustained-release forms, effective half-life may extend to 24-34 hours due to prolonged absorption. Clinical context: time to reach steady state is about 3-5 days.
Primarily metabolized by CYP3A4; also a substrate of P-glycoprotein (P-gp).
Hepatic metabolism via CYP3A4 and CYP2D6; active metabolite phendimetrazine (for some formulations).
Primarily fecal (88%) and renal (8%) as unchanged drug and metabolites; biliary excretion contributes significantly.
Primarily renal (approximately 70-80% unchanged) and biliary/fecal (20-30% as metabolites). Urinary excretion is p H-dependent; acidic urine increases elimination.
84% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 40-50% bound to plasma proteins (albumin).
Apparent volume of distribution approximately 217 L in patients, indicating extensive extravascular distribution.
Approximately 3-5 L/kg. High Vd indicates extensive tissue distribution, including brain.
Oral bioavailability approximately 34% under fasted conditions; food increases exposure (AUC) by 34% but decreases Cmax by 11%.
Oral immediate-release: ~90% (high first-pass metabolism; absolute bioavailability is lower, but systemic exposure is adequate). Oral sustained-release: similar extent but with prolonged absorption.
For GFR ≥ 30 m L/min: no adjustment. For GFR < 30 m L/min: not recommended.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²). For moderate impairment (e GFR 30-59 m L/min/1.73 m²), reduce dose to 15 mg once daily.
Child-Pugh A: no adjustment; Child-Pugh B: reduce to 40 mg; Child-Pugh C: avoid use.
Contraindicated in Child-Pugh class C cirrhosis. In Child-Pugh class A or B, initiate at 15 mg once daily and titrate cautiously to maximum 30 mg once daily.
Safety and efficacy not established; no recommended dose.
Not recommended for pediatric patients under 16 years of age due to lack of safety and efficacy data.
No specific dose adjustment; monitor for increased toxicity due to age-related renal impairment.
Initiating at 15 mg once daily is recommended due to increased sensitivity and potential for central nervous system adverse effects; maximum dose 30 mg once daily.
Fatal and serious toxicities including infections, hyperglycemia, hypertension, non-infectious pneumonitis, and severe cutaneous reactions have occurred.
None.
Monitor for infections; manage hyperglycemia and hypertension; monitor for pneumonitis symptoms; avoid in patients with severe hepatic impairment.
Cardiovascular events (hypertension, tachycardia, stroke), psychiatric adverse effects (psychosis, dependence), primary pulmonary hypertension, valvular heart disease, tolerance, withdrawal symptoms, glaucoma, hyperthyroidism, seizure disorder, diabetes (dose adjustment required), elderly patients (higher sensitivity).
None known, but caution in patients with severe hepatic impairment (Child-Pugh C) and those with active serious infections.
Cardiovascular disease (e.g., coronary artery disease, arrhythmias, hypertension), hyperthyroidism, glaucoma, agitated states, history of drug abuse, MAOIs (concurrent or within 14 days), hypersensitivity to sympathomimetics.
Avoid grapefruit, grapefruit juice, and Seville oranges as they may increase drug exposure. No other specific food interactions reported.
Avoid excessive caffeine intake (e.g., coffee, tea, cola, energy drinks) as it may potentiate CNS and cardiovascular effects. Grapefruit juice may alter drug metabolism; avoid concurrent consumption. Maintain a balanced, reduced-calorie diet as part of the weight loss plan. Alcohol should be avoided due to potential additive CNS effects.
ALIQOPA (copanlisib) is a PI3K inhibitor. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, copanlisib was teratogenic and embryotoxic at maternal exposures below the recommended human dose. First trimester: High risk of structural anomalies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios; potential for fetal PI3K pathway disruption. Advise women of childbearing potential to use effective contraception during treatment and for at least 1 month after the last dose.
FDA Pregnancy Category X. First trimester: Increased risk of oral clefts and cardiac malformations with amphetamine use. Second and third trimesters: Risk of premature delivery, low birth weight, and neonatal withdrawal syndrome. Avoid use in pregnancy.
No data on the presence of copanlisib in human milk, its effects on the breastfed child, or on milk production. Due to the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 1 month after the last dose. M/P ratio: unknown.
Excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infants (irritability, poor feeding). Contraindicated during breastfeeding.
No specific dosing adjustments for pregnancy are established. The physiological changes of pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may affect copanlisib pharmacokinetics, but data are lacking. Use during pregnancy should be avoided unless the potential benefit outweighs the risk. If treatment is necessary, consider therapeutic drug monitoring if available, and monitor for toxicity.
Contraindicated in pregnancy; no dose adjustments recommended.
ALIQOPA (copanlisib) is a PI3K inhibitor with significant toxicity including hyperglycemia, hypertension, and infections. Monitor blood glucose and blood pressure closely during infusion. Premedicate with antihistamines and corticosteroids to reduce infusion-related reactions. Consider Pneumocystis jirovecii pneumonia prophylaxis due to immunosuppression.
Fastin (phentermine) is a sympathomimetic amine indicated for short-term (up to 12 weeks) monotherapy for obesity. It should be used in conjunction with a reduced-calorie diet and exercise. Avoid co-administration with MAOIs or within 14 days of MAOI use due to hypertensive crisis risk. Use with caution in patients with hypertension, diabetes, or history of drug abuse. Monitor blood pressure and heart rate regularly. Tachyphylaxis may develop; discontinue if tolerance occurs. Do not use in patients with advanced arteriosclerosis, hyperthyroidism, glaucoma, or agitated states.
Report any signs of infection (fever, cough, burning urination) immediately.,Monitor blood sugar levels regularly as this drug can cause high blood sugar.,Check blood pressure at home and report elevations.,Avoid grapefruit and Seville oranges during treatment.,Use effective contraception during treatment and for 1 month after last dose.
Take Fastin exactly as prescribed, usually once daily in the morning to avoid insomnia.,Do not crush or chew the extended-release capsule; swallow whole.,Avoid taking late in the day to prevent difficulty sleeping.,Report any chest pain, palpitations, shortness of breath, or dizziness immediately.,Do not increase dose or take more frequently than prescribed; risk of dependence and side effects.,Fastin is for short-term use only (up to 12 weeks) and should be combined with a reduced-calorie diet and exercise.,Do not use if you have taken an MAO inhibitor in the last 14 days.,Avoid alcohol and other CNS stimulants (e.g., caffeine in large amounts) as they may increase side effects.,Do not stop abruptly; follow your doctor's instructions for tapering off.,Keep out of reach of children; misuse can cause severe cardiac toxicity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALIQOPA vs FASTIN, answered by our medical review team.
ALIQOPA is a PI3K Inhibitor Antineoplastic that works by ALIQOPA (copanlisib) is a phosphatidylinositol 3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms. It induces apoptosis and inhibits proliferation in malignant B-cell lines.. FASTIN is a Sympathomimetic Anorectic that works by Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALIQOPA and FASTIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALIQOPA is: 60 mg intravenously over 1 hour on days 1, 8, and 15 of a 28-day cycle.. The standard adult dose of FASTIN is: 30 mg orally once daily in the morning, administered as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALIQOPA and FASTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALIQOPA is classified as Category C. ALIQOPA (copanlisib) is a PI3K inhibitor. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to a pregnant woman. There are no adequate . FASTIN is classified as Category C. FDA Pregnancy Category X. First trimester: Increased risk of oral clefts and cardiac malformations with amphetamine use. Second and third trimesters: Risk of premature delivery, lo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.